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Previous studies of brain single-photon emission tomography (SPECT) showed changes of regional cerebral blood ﬂow (rCBF)
in migraineurs during prodromes or headache attacks. Little is known about how successful medication of migraine prevention
can reﬂect rCBF in migraineurs. We highlighted alternation of brain SPECT ﬁndings in a migraineur with aura before and after
prophylactictreatmentwithlomerizine,acalciumchannelblocker.A70-year-oldmanwithmigrainedevelopedvisualdisturbance
frequently at walking exercise for the recent 3 months. After this visual attack, a mild-degree of throbbing headache occured
occasionally. Brain SPECT using 99mTc-ethyl cysteinate dimer was performed at interictal time of migraine. Brain SPECT before
lomerizine treatment revealed hypoperfusion in the frontal, parietal, and occipital regions. He was diagnosed with recurrence of
migraine with aura (MA). Lomerizine (10mg/day, po) was administered for 3 months. MA and visual aura without headache
were dramatically improved. Migraine attacks and visual disturbance were not induced at exercise. At 3 months after lomerizine
medication, brain SPECT showed remarkable increase of rCBF. These SPECT changes of our patient indicated that antimigraine
mechanism of lomerizine could contribute to restoration of cerebral hypoperfusion.
1.Introduction
Regional cerebral blood ﬂow (rCBF) studies have been
employed to investigate the pathophysiology of migraine
headache [1–3]. The introduction of brain single-photon
emission computed tomography (SPECT) using technetium
Tc 99m- (99mTc-) labelled hexamethylpropyleneamine oxi-
me(HMPAO)orethylcysteinatedimer(ECD)hasfacilitated
assessment of rCBF. A number of rCBF studies using Tc99m
H M P A Oo rE C DS P E C Th a v eb e e nr e p o r t e di np a t i e n t s
with migraine during prodromes or headache phases [3–
8]. However, little is known about the relationship between
migraine preventative medication and rCBF. Lomerizine, 1-
(bis(4-ﬂuorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl) pi-
perazine dihydrochloride, is a calcium channel blocker with
antimigraine properties [9]. This preventative drug is often
used in Japan [10–13]. We ﬁrst report a unique case in
which prophylactic treatment with lomerizine recovered
brain hypoperfusion on 99mTc ECD SPECT during interictal
period, in addition to dramatic amelioration of migraine
attacks.
2.CaseReport
A 70-year-old man developed visual disturbance frequently
at walking exercise for the recent 3 months. Visual dis-
turbance consisted of scintillating scotoma in both eyes,
which continued 5–20 minutes. After this visual attack, a
mild-degree of throbbing headache occured occasionally.
He had prior history of migraine with aura (MA) and
without aura (MO) from 30 years of age. After 60 years
of age, migraine attacks were decreased to a few times
per one year. Physical and neurological examination was
normal during interictal periods. Neuro-ophthalmic exam-
ination was normal. Routine laboratory tests suggested mild
degree of diabetes mellitus. Fasting blood sugar level was
144mg/dL, and hemoglobin A1c was 6.6% (normal 4.3–
5.8). Cerebrospinal ﬂuid study was normal. Brain magnetic2 International Journal of Molecular Imaging
Table 1: Changes of regional cerebral blood ﬂows before and after
lomerizine administration.
Before lomerizine After lomerizine
R i g h tL e f tR i g h t L e f t
Callosomarginal region 47.3 47.4 59.0 59.4
Precentral region 44.8 50.7 59.4 60.0
Central region 45.2 47.6 67.7 63.4
Parietal region 41.7 43.8 61.0 57.6
Angular region 44.3 46.7 59.4 60.0
Temporal region 48.1 50.6 52.4 51.9
Posterior region 48.8 44.2 58.7 58.6
Pericallosal region 53.0 54.1 59.8 59.9
Lenticular nucleus 53.6 52.8 51.1 49.0
Thalamus 48.2 53.1 49.2 51.7
Hippocampus 46.0 42.2 45.1 43.7
Cerebellar hemisphere 58.5 59.2 57.9 57.4
Data were shown in mL/100 g/min.
resonance imaging and angiography were not remarkable.
Electroencephalogram was normal.
2.1. Measurement and Analyses of rCBF. Brain SPECT
scanning with 99mTc-ECD was performed at the interictal
time of migraine. SPECT was scanned at 10 minutes after
intravenous bolus injection of 1.5mL (600MBq), 99mTc-
ECD SPECT examination was performed using a rotating
γ-camera (Prism 3000; Picker Corp. USA). Brain SPECT
data were analyzed by the following two methods. One of
SPECT analyses used the revised version of 3-dimensional
stereotaxic region of interest template (3DSRT) by Takeuchi
et al. [14]. A total of 636 ROIs were set in bilateral
cerebral cortexes and cerebellar hemispheres. Global CBF
was calculated from all data of 636 ROIs in whole brain,
including both cerebral hemispheres and cerebellum. SPECT
images were divided as regional CBF into 24 symmetrical
(right and left) regions per patient: the callosomarginal,
the precentral, the central region, the parietal region, the
angular region, the temporal region, the posterior region,
the pericallosal region, the lenticular nucleus, the thalamus,
the hippocampus region and the cerebellar hemisphere.
Quantiﬁcation of rCBF was assessed using the noninvasive
Patlak plot method without blood sampling [15]. Data of
global and regional CBFs were shown in mL/100g/min.
Another method was analyzed by easy Z-score imaging
system (eZIS).
2.2. rCBF Alternation before and after Lomerizine Administra-
tion. Brain 99mTc-ECD SPECT before lomerizine treatment
revealedhypoperfusioninthefrontal,temporal,parietal,and
occipital lobes (Table 1). Reduction of rCBF was detected
predominantly in the right hemisphere (Figure 1). He was
diagnosed with recurrence of MA. Lomerizine (10mg/day,
po) was administered for 3 months. MA or visual aura
without headache was dramatically improved. There were
no migraine attacks and visual disturbance whenever he
walked and exercised for long time. The second 99mTc-ECD
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Figure 1: Brain 99mTc-ECD SPECT imaging before lomerizine
treatment, CBF is decreased in bilateral frontoparietal and the left
occipital regions on eZIS imaging.
SPECT was performed. As compared to pretreatment with
lomerizine,rCBFwasincreasedinmostofthecerebralcortex
(Table 1). Restoration of frontoparietal hypoperfusion was
found on eZIS imaging (Figure 2).
3. Discussion
We showed that prophylactic treatment with lomerizine
amelioratedbrainhypoperfusionduringtheinterictalperiod
in a patient with MA, together with complete prevention of
migraine attacks and visual auras.International Journal of Molecular Imaging 3
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Figure 2: Brain 99mTc-ECD SPECT imaging after lomerizine
treatment. As compared to pretreatment with lomerizine, CBF is
increased in the bilateral frontoparietal regions on eZIS imaging.
Cerebral hypoperfusion is improved markedly.
Lomerizine, an antimigraine calcium channel blocker,
is prescribed widely in Japanese migraineurs [10–13].
Eﬀectiveness of this prophylactic medication is approx-
imately 50%. Lomerizine belongs to the same class of
diphenylpiperazine-type calcium antagonists as ﬂunarizine
[9], and this drug is prescribed for migraine prophylaxis in
Japan. Previous clinical trials of lomerizine suggested that
this drug reduced the frequency of migraine attacks over
12 weeks [10–12]. Propranolol, amitriptyline, and valproate
sodium are used internationally as preventative medication.
Little is known about how these drugs inﬂuence rCBF on
brain SPECT during the headache attack or the interictal
phase in migraineurs. Prophylactic eﬀects of magnesium
citrate supplementation (600mg/day, po) were assessed by
meansofclinicalevaluation,visualevokedpotential,andsta-
tistical parametric mapping of brain SPECT before and after
3 months treatment. Magnesium treatment signiﬁcantly
increased CBF in the inferolateral frontal, inferolateral tem-
poral, and insular regions [16]. Previous studies disclosed
antimigraine eﬀects of lomerizine in animal models [17–20].
Inhibitoryeﬀectsoflomerizineonthecorticalhypoperfusion
and expression of c-Fos-like immunoreactivity induced by
spreading depression in anaesthetized rats were mediated
via the eﬀects of Ca2+-entry blockade, which may include
an increase in CBF and the prevention of excessive Ca2+
inﬂux into brain cells [17]. These results provide the
possibility that lomerizine may potentiate CBF and inhibit
cortical spreading depression in migraine [17]. Other animal
experiments suggested therapeutic eﬀects of lomerizine on
CBF. Lomerizine had a greater eﬀect on CBF than on blood
pressure and heart rates in anaesthetized rats and beagle
dogs [18]. This drug is reported to inhibit voltage-dependent
Ca2+ channelsand5-hydroxytryptamine(5-HT)2A receptors,
leading to suppression of 5-HT-induced contraction in
rat basilar artery [19]. Recent study has disclosed that
lomerizine recovered visual function in an experimental
animal model of optic nerve injury [20]. Therefore, these
experimental proﬁles supported that lomerizine could be
clinically eﬀective in cerebral circulatory disturbances, such
as migraine status. We ﬁrst highlighted therapeutic eﬀects
of lomerizine on rCBF in a migraineur with aura. This
antimigraine drug can regulate rCBF during the interictal
phaseinmigraineurs.FurtherSPECTstudieswithnumerous
migraineurs are needed to elucidate the precise prophylactic
mechanism of lomerizine.
4. Conclusions
After lomerizine administration had improved MA or visual
aura in our patient, brain SPECT revealed restoration of
decreased CBFs during the interictal period. Clinicoradio-
logical features of our patients indicated that antimigraine
mechanism of lomerizine could contribute to alleviation of
interictal cerebral hypoperfusion.
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